

State of Oklahoma SoonerCare

Ayvakit™ (Avapritinib) Prior Authorization Form

Member Name:	Date of Birth:	Member ID#:
Drug Information		
Pharmacy Billing (NDC:) Start Date (or date of next dose):
Dose:	Regimen:	
Billing Provider Information		
Pharmacy NPI:	Pharmacy Name:	
Pharmacy Phone:	Pharmacy Fa	nx:
Prescriber Information		
Prescriber NPI:	Prescriber Name:	
Prescriber Phone:	Prescriber Fax:	Specialty:
Criteria		
 Gastrointestinal Stromal Tumor (GIST) A. Is diagnosis unresectable or metastatic GIST? Yes No B. Does member have a PDGFRA exon 18 mutation (including PDGFRA D842V mutations)? Yes No Advanced Systemic Mastocytosis (AdvSM) Diagnosis A. Please select one of the following:		
For Continued Authorization: 1. Date of last dose: 2. Does member have any evidence 3. Has the member experienced a lf yes, please specify adverse react	dverse drug reactions relate	ed to avapritinib therapy? YesNo
Prescriber Signature: Date: I certify that the indicated treatment is medically necessary and all information is true and correct to the best of my knowledge. Failure to complete this form in full will result in processing delays.		

PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:

University of Oklahoma College of Pharmacy Pharmacy Management Consultants Product Based Prior Authorization Unit

> Fax: 1-800-224-4014 Phone: 1-800-522-0114 Option 4

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.

Pharm – 163 3/5/2024